ArticleMucosal immunology2018

The JAK inhibitor ruxolitinib reduces inflammation in an ILC3-independent model of innate immune colitis.

A M Overstreet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.